Based on preclinical work, the transient increase in eosinophils observed in asthma and CRSwNP patients may be related to blockade of IL‐4Rα with dupilumab reducing eotaxin production, thus inhibiting eosinophil chemotaxis and tissue infiltration.15 The gene discussed is IL4R; the disease is asthma.